Who
Grant Yonehiro
Chief Operating Officer
Company insider
Files Form 4 as: Chief Operating Officer, Bolt Biotherapeutics; Senior Vice President, Maxygen.
In numbers
- Trades disclosed
- 57
- Buys
- 3
- Sells
- 3
- Bought
- $9,000
- Sold
- $88K
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 3 Mar 2008
- Last trade
- 18 Sep 2026
- Last filed
- 21 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 18 Sep 2026filed 21 Sep 2026 | BOLT Bolt BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $22K6,850 at $3.24 | filing |
| 18 Sep 2026filed 21 Sep 2026 | BOLT Bolt BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $22K6,850 at $3.24 | filing |
| 17 Sep 2026filed 21 Sep 2026 | BOLT Bolt BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $16K4,909 at $3.32 | filing |
| 17 Sep 2026filed 21 Sep 2026 | BOLT Bolt BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $16K4,909 at $3.32 | filing |
| 16 Sep 2026filed 21 Sep 2026 | BOLT Bolt BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $5,3481,417 at $3.77 | filing |
| 16 Sep 2026filed 21 Sep 2026 | BOLT Bolt BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $5,3421,417 at $3.77 | filing |
| 28 Jan 2026filed 4 Feb 2026 | BOLT Bolt Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 28 Jan 2026filed 4 Feb 2026 | BOLT Bolt Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 12 Dec 2025filed 16 Dec 2025 | BOLT Bolt Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,214 | filing |
| 12 Dec 2025filed 16 Dec 2025 | BOLT Bolt Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —3,214 | filing |
| 12 Dec 2025filed 16 Dec 2025 | BOLT Bolt Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —660 | filing |
| 12 Dec 2025filed 16 Dec 2025 | BOLT Bolt Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —660 | filing |
| 12 Dec 2025filed 16 Dec 2025 | BOLT Bolt Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —822 | filing |
| 12 Dec 2025filed 16 Dec 2025 | BOLT Bolt Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —822 | filing |
| 12 Dec 2025filed 16 Dec 2025 | BOLT Bolt Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,653 | filing |
| 12 Dec 2025filed 16 Dec 2025 | BOLT Bolt Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —1,653 | filing |
| 12 Dec 2025filed 16 Dec 2025 | BOLT Bolt Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,642 | filing |
| 12 Dec 2025filed 16 Dec 2025 | BOLT Bolt Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —4,642 | filing |
| 12 Dec 2025filed 16 Dec 2025 | BOLT Bolt Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,142 | filing |
| 12 Dec 2025filed 16 Dec 2025 | BOLT Bolt Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —2,142 | filing |
News
Bolt Biotherapeutics (NASDAQ:BOLT) COO Grant Yonehiro Sells 6,850 Shares of Stockthemarketsdaily.com · 21 Sep 2026
1 headline in the last 90 days name Grant Yonehiro; 0 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.